receptors has not previously been studied in this model.
In this work, we evaluate the possible involvement of EGFR flasks were incubated for 24 h and the conditioned medium was removed, Animals were given BBN at concentrations of 0.01% or 0.05% (v/v) in filtered through a 0.2 µm pore filter and used immediately. The mitogenic their drinking water for 20 weeks (the BBN solution was prepared freshly activity of the conditioned medium was assessed using a rat bladder carcinoma every 2-3 days). Mice were killed when they presented symptoms of weakness cell line (NBT-II) in the presence or absence of a specific EGFR inhibitor (between 1 and 10 weeks after the end of the treatment). Part of each tumour (AG1478). NBT-II cells were seeded in DMEM containing 10% FCS in 96-was fixed in 10% formalin solution and routinely processed for haematoxylin well cell culture plates at a density of 2.5 ϫ 10 4 cells/well. They were and eosin staining. The rest of the tumour was immediately frozen in liquid incubated until they reached confluence, washed twice with DMEM alone nitrogen and stored at -80°C until used for RNA isolation. Normal bladders and then incubated for 24 h in serum-free medium. Cells were incubated for were obtained from untreated C57BL/6 (n ϭ 5) and B6D2F1 (n ϭ 5) mice.
a further 20-24 h in BC57-conditioned medium at various dilutions in serumUrothelium was separated mechanically from the underlying muscle layer, free medium with and without 1 µM AG1478. Proliferation was then assayed frozen in liquid nitrogen and stored at -80°C until used for RNA isolation.
by [ 3 H]thymidine incorporation as described above.
Cell lines
RT-PCR analysis Seven chemically induced mouse bladder carcinoma cell lines (BC13, BC29, Total RNA was extracted by caesium chloride ultracentrifugation (30,31) and BC30, BC46, BC57, BC58 and BC59) were established in our laboratory used as the template for first-strand cDNA synthesis by random priming, as from tumours that developed in C57BL/6 mice treated with 0.05% BBN in previously described (32, 33) . The amount of mRNA was determined by semitheir drinking water, using the protocol described by Dubeau and Jones (27).
quantitative radioactive RT-PCR, using TATA-binding protein (TBP) as an The NBT-II cell line, derived from a chemically induced rat bladder carcinoma internal control, as previously described (34) . The number of cycles was (28), was obtained from Professor Marc Marel (University Hospital, Gent, selected so as to be in the exponential part of the PCR reactions. The sequence Belgium).
of the primers, and the sizes of the amplified fragments are given in BC cell lines were cultured in DMEM-F12ϩ (a 1:1 mixture of Ham's F12 Table 1 . The PCR-amplified products were subjected to electrophoresis in 8% and Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% polyacrylamide gels. Signals were quantified with a Molecular Dynamics heat-inactivated fetal calf serum (FCS), 1 µg/ml insulin, 2 mM L-glutamine, 300 PhosphorImager (Molecular Dynamics, Sunnyvale, CA). There was no 10 mM HEPES, 50 nM hydrocortisone, 5 µg/ml apotransferrin, 5 nM sodium amplification if reverse transcriptase was omitted from the reverse transcripselenite, 100 units/ml penicillin and 100 µg/ml streptomycin). The NBT-II tion reaction. cell line was cultured in DMEM supplemented with 10% FCS (29) . All cell Lysate preparation, western blot analysis and immunoprecipitation lines were incubated at 37°C in a humidified atmosphere in 5% CO 2 .
DMEM-F12 supplemented with 10 mM HEPES, 5 µg/ml transferrin, 5 nM Bladder cancer cell lines were seeded in six-well plates in DMEM-F12ϩ. sodium selenite, 100 units/ml penicillin and 100 µg/ml streptomycin was used
The cells were incubated for 24 h, washed twice with PBS Ca 2ϩ /Mg 2ϩ , then for culture in serum-free medium conditions. incubated in serum-free medium. When the cells reached confluence, they were exposed to various concentrations of AG1478 for 16 h. They were then Tritiated thymidine incorporation incubated for a further 10 min, with or without 100 ng/ml mouse EGF, and Cell proliferation was assayed by measuring the incorporation of [ 3 H]thymidscraped into lysis buffer (50 mM Tris-HCl pH 7.4, 1% Nonidet P-40, 0.25% ine. Cells were plated at a density of 6000 cells/well in DMEM-F12ϩ and sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 1 mM phenylmethylsulfonincubated for 24 h to facilitate attachment. They were then washed three ylfluoride, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 100 µM sodium orthovanadate, times with phosphate-buffered saline containing Ca 2ϩ /Mg 2ϩ (PBS Ca 2ϩ / 50 mM NaF). Lysates were kept on ice for 5-10 min, centrifuged for 10 min Mg 2ϩ ) and incubated for 48 h in serum-free medium. Growth factors or at 4°C and 14 000 ϫ g, and the supernatant was collected. Protein concentration inhibitors were added and the cells were incubated for a further 20-24 h.
was determined with the Bradford protein assay. Lysates were then subjected Cells were then labelled by incubation for 4 h with 1 µCi/well of [ 3 H]thymidine.
to western blotting or immunoprecipitation. At the end of the labelling period, the cells were treated with trypsin and For western blot analysis, the proteins (50 µg) in each extract were resolved transferred to FiltermatA membrane with a Tomtech apparatus (Wallac Inc., by 7.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDSGaithersburg, MD). After several washes, the membrane was dried and the PAGE), transferred to PVDF membrane (Immobilon; Millipore, Bedford, cell-bound radioactivity was determined in a 96-well scintillation counter MA), and incubated with mouse anti-phosphotyrosine monoclonal antibodies (Microbeta counter, Wallac Inc.).
(Py20 and 4G10) at a dilution of 1:5000. Bound antibodies were detected Preparation of conditioned medium and effect on cell proliferation with an anti-mouse horseradish peroxidase-conjugated secondary antibody, using an ECL kit. Conditioned medium from BC57 cells was collected and prepared as follows. Cells were cultured in 24 cm 2 tissue culture flasks (Falcon) in DMEM-F12ϩ.
For immunoprecipitation analysis, lysates were incubated overnight at 4°C with 12 µg of a sheep polyclonal anti-EGFR antibody. Immunocomplexes When the cells were 60-70% confluent, they were washed twice with PBS were collected by incubation with 30 µl of protein G-agarose for 2 h at 4°C. Immunoprecipitated proteins were washed three times in lysis buffer, resolved by SDS-PAGE (7.5%) and immunoblotted with mouse anti-phosphotyrosine monoclonal antibodies. Bound antibodies were detected as described above. To detect EGFR after immunoprecipitation, the blot was stripped of primary and secondary antibodies and reprobed with the sheep polyclonal anti-EGFR antibody. Bound antibody was detected as described above, using an antisheep secondary antibody.
Results

Expression of EGFR and EGF family members in BBN-induced mouse bladder tumours
Fourteen C57B6 and 26 B6D2 mice were treated for 20 weeks with BBN. At autopsy, all the treated mice presented highly invasive carcinoma of the bladder. Carcinomas exhibited urothelial, squamous or anaplastic differentiation or both urothelial and squamous differentiation. All the tumour samples used in this expression analysis study consisted primarily of tumour cells: samples adjacent to the pieces used for RNA preparation were analysed histologically by haematoxylin/ eosin staining and were found to contain Ͼ80% tumour cells. Control urothelia were obtained from the bladders of untreated animals by mechanically separating this compartment from the underlying bladder muscle layer. Desmin, a smooth muscle marker, was used to test the quality of the separation. As expected, desmin mRNA was detected exclusively in the muscle layer samples (data not shown).
We assessed the levels of mRNA for EGFR and its ligands, EGF, TGFα, amphiregulin, HB-EGF and BTC, in these bladder tumours and in bladder urothelia from untreated animals (five C57B6 mice and five B6D2 mice). We measured mRNA levels by semi-quantitative RT-PCR, using TBP as an internal standard. Two examples of quantification are given in Figure   Fig We investigated the role of EGFR in the autonomous growth displayed by the various cell lines more directly, by studying esis, we derived seven cell lines from seven C57B6 mouse bladder tumours induced by BBN (BC13, BC29, BC30, BC46, the effects on proliferation of an EGFR tyrosine kinase-specific inhibitor (AG1478). At a concentration of 1 µM, AG1478 had BC57, BC58 and BC59). All these cell lines grew in serum-free conditions, indicating that they were capable of autonomous a marked inhibitory effect (60-90%) on thymidine incorporation in the seven bladder cell lines grown in serum-free growth. We then used semi-quantitative RT-PCR to evaluate the levels of mRNA for EGFR and its ligands in four of these conditions ( Figure 3 ). This effect was dose-dependent, with an ID 50 of 0.2 µM for the BC57 cell line (data not shown). cell lines cultured in serum-free conditions. All the cell lines tested expressed both EGFR and at least one of its ligands;
Several studies have shown that EGFR ligands can induce amphiregulin, HB-EGF and BTC in BC57 and BC58, in the presence or absence of the EGFR inhibitor, AG1478. BC57 the conditioned medium of the BC57 cell line contained growth and BC58 were used in this study because they produced these factor activity able to activate EGFR. The NBT-II cell line, EGFR ligands (Figure 2) . A concentration of 1 µM AG1478 which has limited growth in the absence of serum and can significantly decreased the levels of mRNA for amphiregulin, respond to EGFR ligands (29) , was treated with BC57-HB-EGF and BTC in both cell lines, and decreased TGFα conditioned medium in the presence or absence of the EGFRmRNA levels in the BC58 cell line only (Figure 4) . specific inhibitor AG1478 ( Figure 6 ). Conditioned medium of An EGFR-neutralizing antibody inhibited the proliferation of the BC57 cell line strongly stimulated proliferation of the a mouse bladder cell line NBT-II cell line. This stimulation was completely abolished if the cells were incubated with 1 µM AG1478 together with the We investigated whether EGFR was activated within the cell or at the cell surface. For this purpose, we evaluated the ability conditioned medium. of the mouse monoclonal antibody LA22, directed against the Inhibition of EGFR autophosphorylation by EGFR tyrosine extracellular domain of human EGFR, to inhibit thymidine kinase inhibitor incorporation by the bladder cancer cell line BC57 in serum-
The probable involvement of EGFR in the autonomous growth free medium. LA22 antibody (50 µg/ml) decreased thymidine of various mouse bladder cell lines led us to investigate the incorporation in BC57 cells by 45%, whereas MRC Ox-34, a tyrosine phosphorylation of EGFR in the presence and absence control antibody of the same isotype (IgG2a) had no effect of exogenous EGF. In the BC29 cell line, in serum-free ( Figure 5 ). medium and in the absence of EGF, a protein of the same Conditioned medium of the BC57 bladder cancer cell line molecular weight as EGFR (170 kDa) was detected by western contains growth factor activity that can stimulate proliferation blotting with anti-phosphotyrosine antibodies. As expected, a of the NBT-II cell line through EGFR band of identical molecular weight, but giving a stronger signal, was observed if cells were incubated with exogenous The inhibition by an EGFR antibody of the autonomous growth of BC cell lines suggested that activation of EGFR occurred EGF ( Figure 7A ). Incubation of BC29 cells with AG1478, a specific EGFR tyrosine kinase inhibitor, resulted in a lower at the cell surface. This receptor activation may be mediated by a ligand, secreted by the cells, that subsequently binds to level of phosphorylation of the 170 kDa band. This effect was concentration dependent ( Figure 7A ). Immunoprecipitation EGFR on the cell surface. We therefore investigated whether with an anti-EGFR antibody followed by western blotting with anti-phosphotyrosine antibodies confirmed that the 170 kDa band corresponded to EGFR ( Figure 7B ). As expected, no phosphorylation was detected if the cells were treated with AG1478, although EGFR was present in the immunoprecipitates ( Figure 7B ). Two phosphorylated proteins of~100 and 120 kDa were also immunoprecipitated with anti-EGFR antibodies. The phosphorylation of these proteins was inhibited by AG1478. These proteins may be part of the EGFR signal transduction cascade. Similar results were obtained with the BC57 cell line (data not shown). a number of human tumours and tumour cell lines have been EGFR may be activated in tumour cells by several mechanisms that are not mutually exclusive: (i) an increase in the expression of EGFR ligands may be the primary event, which then triggers EGFR activation; (ii) overexpression of EGFR; (iii) abolition of the negative feedback regulation of EGFR (39); (iv) as EGFR ligands are all initially synthesized in a membrane-bound form, proteolytic cleavage to release a soluble mature ligand may be rate-limiting for activation of the receptor; (v) ligand-independent activation of the receptor by trans-activation has also been described recently (40,41). The last four of these mechanisms are not incompatible with the higher levels of ligands observed in mouse bladder tumours and cell lines as ligand overexpression may be induced by EGFR activation, a phenomenon known as autoinduction (35). Consistent with this, we found that the inhibition of EGFR kinase activity by AG1478 considerably reduced overexpression of the various ligands.
EGFR may interact with the EGFR ligands produced by the tumour cells within the cells or at the cell surface. The partial inhibition of EGFR activation by an antibody shows that EGFR activation occurs partly at the cell surface (42,43).
As previously reported, BBN induced invasive bladder tumours of several types in mice (24-26). In this study, we observed squamous cell carcinoma, urothelial cell carcinoma, only two EGFR ligands, EGF and TGFα, has been studied so far (20, 21, 46) . In view of our results in mice, it would be interesting to study other EGFR ligands too. shown to overproduce EGFR. As TGFα is often overexpressed with EGFR, it has been suggested that this EGFR ligand is an Our data strongly suggest that EGFR is involved in bladder tumour progression in mice. This model could be used to autocrine growth factor (9) . In human bladder carcinomas, high EGFR levels have been reported mainly for high-grade study in detail the involvement of EGFR in the early stages of tumour progression, which are difficult to study in humans. and high-stage tumours and have been found to be associated with an increase in the risk of tumour progression (19, 36) . A Metastases are observed in BBN-treated mice (47) so this model could also be used to study late stages of tumour limited number of studies performed on human bladder tumour cell lines have shown that EGFR is involved in cell growth progression. The various ligands of the EGFR are not equivalent in terms of the activation of various pathways from EGFR, (37) and motility (38) .
In this study, we provide evidence that EGFR is involved ErbB3, ErbB4 dimers or ErbB heterodimers and duration of the activation signal (48-51). Mice with these genes knocked in BBN-induced mouse bladder tumours: (i) the genes encoding EGFR and its ligands, TGFα, amphiregulin, HB-EGF and out for EGF, TGFα and amphiregulin are available and viable (52-54), and the use of such transgenic mice could be used BTC, were co-expressed in bladder tumours and in derived cell lines; (ii) the levels of mRNA for amphiregulin, HB-EGF to determine the respective roles played by the various ligands in this bladder tumour model. and BTC in tumours and derived cell lines were higher than those in normal urothelium; (iii) proliferation of the bladder Due to the probable role of EGFR in human tumours, intensive studies have been carried out in which EGFR cancer cell lines was inhibited by AG1478, a tyrosine kinase inhibitor specific for EGFR; (iv) proliferation of the bladder signalling was specifically blocked (22,23). Four potential strategies using EGFR as a therapeutic target are now being cancer cell lines was inhibited by an antibody directed against the extracellular domain of human EGFR; (v) EGFR was studied: (i) monoclonal antibody alone; (ii) immunotoxins; (iii) monoclonal antibodies in conjunction with standard phosphorylated in the cell lines grown in serum-free medium and this phosphorylation was inhibited by treatment of the chemotherapy; and (iv) pharmacological agents inhibiting EGFR or downstream components of the EGFR pathway. As cells with AG1478; and (vi) the conditioned medium of one of the cell lines (BC57) was found to contain EGFR-stimulating EGFR is probably involved in BBN-induced bladder tumour in mice, this animal model could be used to study protocols activity, as it increased proliferation of the NBTII cell line and this stimulation was blocked by the EGFR tyrosine kinase targeting the EGFR or EGFR pathway. EGFR inhibitors may act at two levels, blocking the activity of the receptor but inhibitor, AG1478. 
